Latest News

  • Universal Newborn Screening for Congenital CMV Would Have a Significant Impact

    Diagnostics World | It is time for clinical laboratories to push for cytomegalovirus (CMV) testing as part of the standard newborn screening process. We have seen some progress on this front recently, with Minnesota becoming the first state in the US to approve universal CMV screening at birth. However, Minnesota should not stand alone; newborns everywhere would benefit from CMV screening.

    Feb 23, 2024
  • Electronic White Blood Cell Tracker Developed For Near-Patient Testing

    Diagnostics World | A revolution is underway in the diagnostics world that is reminiscent of what transpired in the computing field before the advent of PCs and smartphones. The unimagined possibilities of today will come from democratizing technology so that instead of sending patients to the lab, the lab will get sent to patients—and, ultimately, be available to them in the form of at-home testing kits.

    Feb 21, 2024
  • Measuring Sleep Apnea Severity With Sweat

    Diagnostics World | Researchers in Spain are advocating the use of sweat in metabolomics studies to measure the severity of sleep apnea. It’s an ideal alternative to blood and urine because the sampling is noninvasive and accessible, and the biofluid doesn’t require much manipulation by the test operator that can introduce variability.

    Feb 20, 2024
  • Texas Building First End-To-End Wastewater Pathogen Monitoring System

    Diagnostics World | In the future, it may be possible for people to get a read on viruses circulating in their neighborhood in the same way they now do to assess current weather conditions before hitting the road. The means would be some sort of digitized community health report, an early version of which is already being produced for 10 cities across Texas.

    Feb 15, 2024
  • Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Diagnostics World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years.

    Feb 13, 2024